New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
10:00 EDTFRX, WETF, HK, AWI, PFE, CRM, ZNGA, ORLY, OIS, OPEN, NLSN, MRK, ANGI, CBT, CVX, DVN, DRE, FRC, GPS, GILD, AGNOn the Fly: Analyst Upgrade Summary
Allergan (AGN) upgraded to Buy from Neutral at Citigroup... Angie's List (ANGI) upgraded to Outperform from Market Perform at Barrington... Cabot (CBT) upgraded to Buy from Neutral at SunTrust... Chevron (CVX) upgraded to Strong Buy from Outperform at Raymond James... Devon Energy (DVN) upgraded to Outperform from Neutral at Credit Suisse... Duke Realty (DRE) upgraded to Outperform from Sector Perform at RBC Capital... First Republic (FRC) upgraded to Outperform from Market Perform at Keefe Bruyette,,, Gap (GPS) upgraded to Buy from Neutral at UBS... Gilead (GILD) upgraded to Outperform from Neutral at RW Baird... Merck (MRK) upgraded to Buy from Neutral at SunTrust... Nielsen (NLSN) upgraded to Buy from Hold at Pivotal Research... OpenTable (OPEN) upgraded to Neutral from Sell at Citigroup... Pfizer (PFE) upgraded to Buy from Hold at Jefferies... Salesforce.com (CRM) upgraded to Buy from Neutral at Roth Capital... Zynga (ZNGA) upgraded to Buy from Neutral at UBS... O'Reilly Automotive (ORLY) upgraded to Buy from Neutral at Northcoast... Oil States (OIS) upgraded to Buy from Accumulate at Tudor Pickering... Armstrong World (AWI) upgraded to Buy from Hold at Gabelli... Halcon Resources (HK) upgraded to Neutral from Reduce at Global Hunter... Wisdom Tree (WETF) upgraded to Buy from Neutral at BofA/Merrill... Forest Labs (FRX) upgraded to Overweight from Neutral at JPMorgan.
News For AGN;ANGI;CBT;CVX;DVN;DRE;FRC;GPS;GILD;MRK;NLSN;OPEN;PFE;CRM;ZNGA;ORLY;OIS;AWI;HK;WETF;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
October 9, 2014
05:38 EDTGPSGap downgraded to Market Perform from Outperform at Wells Fargo
Subscribe for More Information
October 8, 2014
18:31 EDTGPSOn The Fly: After Hours Movers
UP AFTER EARNINGS: Ruby Tuesday (RT), up 19.6%... Exar (EXAR), up 13.7% after reporting second quarter revenue guidance... Alcoa (AA), up 2.2%. ALSO HIGHER: Nuance (NUAN), up 2.5% following rumors that Carl Icahn will recommend that Apple (AAPL) buy the company... GrubHub (GRUB), up just under 1% after being initiated with a Buy at CRT Capital. DOWN AFTER EARNINGS: Kofax (KFX), down 20.1% after reporting first quarter revenue and fiscal 2015 revenue guidance below analyst estimates... ARC Group (ARCW), down 17%... E2open (EOPN), down 8.9%. ALSO LOWER: Gap (GPS), down 7.6% following September same store sales data and CEO transition... AMD (AMD), down 7% after announcing CEO transition.
16:50 EDTGPSGap CEO Glenn Murphy says board planned CEO succession
Gap's outgoing chairman and CEO Glenn Murphy stated that the CEO transition to Art Peck was planned in advance and was a part of the company's growth plan. Murphy stated that the board asked him to stay but he is not able to make a personal commitment to be at the company to execute long-term plans. Murphy says he will work closely with Peck during the transition period. Comments made during CEO transition conference call.
16:26 EDTGILDOn The Fly: Closing Wrap
Subscribe for More Information
16:10 EDTAGNAllergan initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:08 EDTGPSGap trades sharply lower in the extended session
The stock is down over 8% to $38.49 in the after hours market. At that price next support is at $37.25. Resistance is at $39.48.
16:05 EDTGPSGap reports September net sales up 1% vs. last year
Subscribe for More Information
16:03 EDTGPSGap names Art Peck to succeed Glenn Murphy as CEO
Gap Inc. announced that Art Peck, the president of its Growth, Innovation and Digital division, has been selected by the board to succeed Glenn Murphy as the company’s next CEO, effective February 1, 2015. Murphy made the personal decision to retire from the company at the end of the fiscal year, allowing for a smooth leadership transition. Peck joined the company in 2005. As part of the transition, Bob Fisher will become non-executive Chairman of the board, and Peck will join the board, effective February 1, 2015.
16:01 EDTGILDOptions Update; October 8, 2014
iPath S&P 500 VIX Short-Term Futures down 2.73 to 29.51. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX PBR AA CLF GILD according to Track Data.
16:01 EDTGPSGap names Art Peck to succeed Glenn Murphy as CEO
Subscribe for More Information
15:49 EDTGILDAchillion, Gilead rise after late breaking abstract for AASLD posted
Shares of Achillion (ACHN) are higher after the company announced this morning that four abstracts have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. Among those four is a late breaker poster presentation providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus infection. Sofosbuvir is sold under the brand name Sovaldi by Gilead Sciences (GILD). In a note to investors, FBR Capital noted that the "surprise" late-breaking poster for the meeting showed a 100% cure rate for the combination therapy. In late afternoon trading, Achillion shares are up 10% to $10.74 while Gilead is up 4.3% to $108.78.
11:14 EDTMRKMerck presents new MK-5172/MK-8742 clinical study data
Merck announced that new data from clinical studies of the company’s investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir, or MK-5172/MK-8742, are scheduled to be presented at the 65th American Association for the Study of Liver Diseases Annual Meeting, also known as The Liver Meeting. The meeting is scheduled to take place from November 7-11. New data will also be presented for MK-3682, formerly IDX21437, as part of its purchase of Idenix Pharmaceuticals.
11:08 EDTMRKLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analyst discusses IMPROVE-IT's regulatory and commercial implications for novel LDL-lowering therapies on an Analyst/Industry conference call to be held on October 9 at 2 pm.
10:55 EDTPFE, MRKLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
10:48 EDTZNGAGlu drops despite Benchmark optimism about Kardashian game
Research firm Benchmark Co. upgraded digital video game maker Glu Mobile (GLUU) to Buy from Hold, based on optimism about the company's upcoming third quarter earnings report. WHAT'S NEW: Glu may report higher than expected third quarter sales and earnings before interest taxes depreciation and amortization on October 29, Benchmark analyst Mike Hickey wrote in a note to investors today. The company may also raise its fourth quarter guidance, Hickey believes. Glu's results are being lifted by the success of the company's "Kim Kardashian: Hollywood" game, the analyst believes. He has a $5.90 price target on the name. WHAT'S NOTABLE: Taking the opposite view on Glu Mobile in an article yesterday was a short-selling blog, TheStreetSweeper. The blog said it "wouldn't be surprised" if the company cut its Q4 guidance, as Kim Kardashian and other Glu games "are fading fast." Company insiders are "selling huge chinks" of the company's shares, added the blog. Northland Capital analyst Darren Aftahi yesterday countered by accusing TheStreetSweeper of "acting as a megaphone" for shorts in the name, trying to drive down the stock in a weak market, and producing an article that is "full of conjecture." The analyst said he thinks the company could beat Q3 revenue expectations by a large amount, potentially producing a "massive short squeeze." OTHERS TO WATCH: Other digital video game makers include Zynga (ZNGA) and King Digital (KING). PRICE ACTION: In early trading, Glu dropped 4% to $4.56.
08:42 EDTAGNSalix shares should be bought on weakness, says Sterne Agee
After Reuters yesterday afternoon reported that Actavis (ACT) plans to make a new merger approach to Allergan (AGN), Sterne Agee believes that Salix's standalone value is $162. The firm expects the shares to reach that level following approval of its Xifaxan IBS-D drug after the February 2015 PDUFA date.
08:09 EDTPFEPfizer presents LP2086 Phase 2 study data
Pfizer announced it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086, or rLP2086, with a licensed quadrivalent human papillomavirus vaccine at IDWeek 2014. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086 and HPV4. Prespecified noninferiority criteria were met for the bivalent rLP2086 antigens studied and three of the four antigens for HPV4. Primary immunogenicity endpoints, measured after the third dose, included geometric mean titers against HPV antigens in Groups 1 and 3 and human complement serum bactericidal assay GMTs against meningococcal group B disease test strains in Groups 1 and 2. Secondary immunogenicity endpoints included the rate of seroconversion to HPV antigens. Safety of bivalent rLP2086 was assessed after concomitant administration with HPV4 or saline. The prespecified noninferiority criteria were met for three of four HPV antigens and both meningococcal group B disease test strains. Seroconversion for all four HPV antigens was achieved by 99% or more of the subjects for the groups that received HPV4 concomitantly with bivalent rLP2086 or with saline. More local reactions occurred following administration of bivalent rLP2086 compared with saline but the incidence of these reactions did not increase with subsequent vaccine administration. The rates of local and systemic reactions were comparable when bivalent rLP2086 was given with HPV4 to bivalent rLP2086 given alone.
07:19 EDTPFE, AGNCBI to hold a conference
Subscribe for More Information
07:18 EDTMRK, GILD, PFEInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
06:23 EDTAGNActavis more inclined to pursue Allergan over Salix, says Citigroup
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use